Daiichi Sankyo signs a $300m deal with Alteogen to develop a subcutaneous version of anti-HER2 cancer drug Enhertu.

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get ...

A high-level overview of Daiichi Sankyo Company, Limited (DSKYF) stock. View (DSKYF) real-time stock price, chart, news, analysis, analyst reviews and more.

View the latest Daiichi Sankyo Co. Ltd. (DSKYF) stock price, news, historical charts, analyst ratings and financial information from WSJ.